المؤلفون: Nunzio Digiacomo, Tommaso De Pas, Giovanna Rossi, Paola Bossi, Erika Stucchi, Fabio Conforti, Emilia Cocorocchio, Daniele Laszlo, Laura Pala, Emma Zattarin, Chiara Catania

المصدر: Current Oncology, Vol 30, Iss 3, Pp 3494-3499 (2023)

مصطلحات موضوعية: transformed SCLC, EGFR, exon 18, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://www.mdpi.com/1718-7729/30/3/265Test; https://doaj.org/toc/1198-0052Test; https://doaj.org/toc/1718-7729Test

الوصول الحر: https://doaj.org/article/4960412eb78643b0975752392593a027Test

المؤلفون: Michael Cekay, Philipp F. Arndt, Rio Dumitrascu, Rajkumar Savai, Andreas Braeuninger, Stefan Gattenloehner, Dagmar Steiner, Fritz Roller, Khodr Tello, Katja Hattar, Werner Seeger, Ulf Sibelius, Friedrich Grimminger, Bastian Eul

المصدر: Frontiers in Oncology, Vol 13 (2023)

مصطلحات موضوعية: non-small cell lung cancer, EGFR mutation, tyrosine kinase inhibitors (TKIs), Osimertinib, EGFR Exon 18 insertion, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fonc.2023.1182391/fullTest; https://doaj.org/toc/2234-943XTest

الوصول الحر: https://doaj.org/article/c9b3ddacb6a3441c99d02d083bd1f2deTest

المؤلفون: Meihui Li, Jing Qin, Fajun Xie, Lei Gong, Na Han, Hongyang Lu

المصدر: Discover Oncology, Vol 13, Iss 1, Pp 1-8 (2022)

مصطلحات موضوعية: L718Q/V mutation of EGFR exon 18, EGFR T790M mutation, Osimertinib, Resistance mechanism, Afatinib, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2730-6011Test

الوصول الحر: https://doaj.org/article/2c7398dc2b51465e9ac4c1f763e61f87Test

المؤلفون: Tatli, A.M., Erdem, D., Goker, E., Celik, E., Demirci, N.S., Sakin, A., Gursoy, P.

مصطلحات موضوعية: Erlotinib, survival rate, survival time, exon, genetics, lung tumor, mutation, Afatinib, Carcinoma, Non-Small-Cell Lung, ErbB Receptors, Erlotinib Hydrochloride, Exons, Gefitinib, Humans, Lung Neoplasms, Protein Kinase Inhibitors, Quinazolines, Exon 18, Exon 20, NSCLC, epidermal growth factor receptor, EGFR protein, human, protein kinase inhibitor, quinazoline derivative, adult, anemia, Article, cancer chemotherapy

العلاقة: Journal of Cancer Research and Clinical Oncology; Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı; https://hdl.handle.net/11499/52935Test; https://doi.org/10.1007/s00432-022-03984-5Test; 149; 865; 875; 2-s2.0-85127494466

الإتاحة: https://doi.org/10.1007/s00432-022-03984-5Test
https://hdl.handle.net/11499/52935Test

المؤلفون: Gursoy P., Tatli A.M., Erdem D., Goker E., Celik E., Demirci N.S., Sakin A.

مصطلحات موضوعية: Afatinib, Erlotinib, Exon 18, Exon 20, NSCLC, epidermal growth factor receptor, gefitinib, EGFR protein, human, protein kinase inhibitor, quinazoline derivative, adult, anemia, Article, cancer chemotherapy, cancer resistance, cancer survival, comparative study, controlled study, diarrhea, drug withdrawal, female, follow up, hypertransaminasemia, interstitial lung disease, major clinical study, male, middle aged, mucosa inflammation, multicenter study

العلاقة: Journal of Cancer Research and Clinical Oncology; Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı; https://doi.org/10.1007/s00432-022-03984-5Test; https://hdl.handle.net/20.500.12831/19454Test; 149; 865; 875; 2-s2.0-85127494466

الإتاحة: https://doi.org/10.1007/s00432-022-03984-5Test
https://doi.org/20.500.12831/19454Test
https://hdl.handle.net/20.500.12831/19454Test

المؤلفون: Pascal Wang, Emmanuelle Fabre, Antoine Martin, Kader Chouahnia, Ambre Benabadji, Lise Matton, Boris Duchemann

المصدر: Frontiers in Oncology, Vol 12 (2022)

مصطلحات موضوعية: NSCLC, uncommon mutation, exon 18, tyrosine kinase inhibitor (TKI), compound mutations, EGFR, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fonc.2022.918855/fullTest; https://doaj.org/toc/2234-943XTest

الوصول الحر: https://doaj.org/article/3581a5abb8ee400bbf490cc96629ef2fTest

المؤلفون: Nadia Ben Jemii, Haifa Tounsi-Kettiti, Hamza Yaiche, Najla Mezghanni, Amira Jaballah Gabteni, Emna Fehri, Chayma Ben Fayala, Sonia Abdelhak, Samir Boubaker

المصدر: Journal of Translational Medicine, Vol 18, Iss 1, Pp 1-20 (2020)

مصطلحات موضوعية: Platelet derived growth factor receptor alpha, Colorectal cancer, RAS status, Mutations exon 18, Immunohistochemistry, Medicine

وصف الملف: electronic resource

العلاقة: http://link.springer.com/article/10.1186/s12967-020-02614-3Test; https://doaj.org/toc/1479-5876Test

الوصول الحر: https://doaj.org/article/7e61269da7af403081e048bae78af069Test

المؤلفون: Erdem, Dilek, Goker, Erdem, Celik, Emir, Demirci, Nebi Serkan, Sakin, Abdullah, Tatli, Ali Murat, Gursoy, Pinar

مصطلحات موضوعية: Exon 20, Exon 18, Erlotinib, Afatinib, NSCLC, Growth-Factor Receptor, Tyrosine Kinase Inhibitor, 1st-Line Treatment, Open-Label, Multicenter, Efficacy, Chemotherapy

العلاقة: Journal Of Cancer Research And Clinical Oncology; Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı; https://hdl.handle.net/11454/76047Test; https://doi.org/10.1007/s00432-022-03984-5Test; SAKIN, Abdullah/0000-0003-2538-8569; Akin Telli, Tugba/0000-0001-6535-6030; bilgin, burak/0000-0003-1717-8246; GOKER, ERDEM/0000-0001-6180-713X; Gursoy, Pinar/0000-0003-1392-6753; Cavdar, Eyyup/0000-0001-5885-3047

الإتاحة: https://doi.org/10.1007/s00432-022-03984-5Test
https://hdl.handle.net/11454/76047Test

المؤلفون: Gursoy, Pinar, Tatli, Ali Murat, Erdem, Dilek, Goker, Erdem, Celik, Emir, Demirci, Nebi Serkan, Sakin, Abdullah

مصطلحات موضوعية: Exon 18, Exon 20, Erlotinib, Afatinib, NSCLC, Growth-Factor Receptor, Tyrosine Kinase Inhibitor, 1st-Line Treatment, Open-Label, Multicenter, Efficacy, Chemotherapy

العلاقة: Journal Of Cancer Research And Clinical Oncology; Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı; https://doi.org/10.1007/s00432-022-03984-5Test; https://hdl.handle.net/11454/85469Test; WOS:000779481900001; 2-s2.0-85127494466

الإتاحة: https://doi.org/10.1007/s00432-022-03984-5Test
https://hdl.handle.net/11454/85469Test

المؤلفون: Selcukbiricik, Fatih, Turkoz, Fatma Paksoy, Gursoy, Pinar, Tatli, Ali Murat, Erdem, Dilek, Goker, Erdem, Celik, Emir, Demirci, Nebi Serkan, Sakin, Abdullah, Atci, Muhammed Mustafa, Bayram, Ertugrul, Telli, Tugba Akin, Bilgin, Burak, Bilici, Ahmet, Akangunduz, Baran, Balli, Sevinc, Demirkazik, Ahmet, Menekse, Serkan, Cavdar, Eyyup, Ozturk, Akin, Bekmez, Esma Turkmen, Turhal, Serdal, Kilickap, Sadettin, Akdeniz, Nadiye, Alan, Ozkan, Yildirim, Hasan Cagri, Oyan, Basak, Aksoy, Asude, Kut, Engin, Katgi, Nuran, Sakalar, Teoman, Akyol, Murat, Ellez, Halil Ibrahim, Topcu, Atakan, Erdogan, Atike Pinar, Pilanci, Kezban Nur, Hedem, Engin, Arak, Haci, Yapar, Burcu, Nart, Deniz, Yumuk, Perran Fulden

مصطلحات موضوعية: Exon 18, Exon 20, Erlotinib, Afatinib, NSCLC, Growth-Factor Receptor, Tyrosine Kinase Inhibitor, 1st-Line Treatment, Open-Label, Multicenter, Efficacy, Chemotherapy

العلاقة: Journal Of Cancer Research And Clinical Oncology; Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı; https://doi.org/10.1007/s00432-022-03984-5Test; https://hdl.handle.net/11499/46751Test; 2-s2.0-85127494466; WOS:000779481900001

الإتاحة: https://doi.org/10.1007/s00432-022-03984-5Test
https://hdl.handle.net/11499/46751Test